Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mystery of persistent swallowing trouble in treated eosinophilic esophagitis explored

NCT ID NCT07708467

Knowledge-focused Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This study looks at people with eosinophilic esophagitis whose symptoms like trouble swallowing or chest pain continue even though their inflammation is under control. Researchers will use special tools to measure how stretchy the esophagus is and how it moves, and also consider whether heightened awareness of symptoms plays a role. The goal is to find better ways to help these individuals.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better understand and treat persistent symptoms in people with eosinophilic esophagitis who are otherwise in remission.
What could go wrong
This is a small, observational study that aims to gather knowledge, not test a new treatment. It may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes adult patients with confirmed eosinophilic esophagitis who are in regular clinical follow-up at one of the referral hospitals participating in the study, have achieved histologic remission, defined as fewer than 15 eosinophils/HPF on esophageal biopsies, but continue to experience persistent symptoms such as dysphagia, chest pain, or food impaction despite stable EoE therapy.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years; 2. Confirmed diagnosis of eosinophilic esophagitis in histological remission (\<15 eosinophils/HPF); 3. Persistent symptoms (e.g., dysphagia, food impaction, chest pain) despite medical or dietary therapy; 4. Stable EoE therapy throughout the study duration (proton pump inhibitors, budesonide, dupilumab, dietary therapies); 5. Signed informed consent. Exclusion Criteria: 1. Previous diagnosis of severe erosive esophagitis (Los Angeles grade C or higher); 2. Previous diagnosis of esophagogastric junction outflow disorders (e.g., achalasia); 3. Systemic diseases involving the esophagus (e.g., scleroderma); 4. Use or initiation during the study of immunosuppressive or biological drugs, or medications affecting esophageal motility (opioids, nitrates, calcium channel blockers); 5. Presence of R3 and/or S1 (according to EREFS).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dysphagia, esophageal are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Deglutition Disorders Dilatation, Pathologic eosinophilic esophagitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dysphagia, esophageal Eosinophilic esophagitis (EOE)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ospedale Maggiore Policlinico di Milano

    Milan, MI, 20122, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.